nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2017-21-1-19-24nefr-217Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEРАСШИРЕНИЕ ПРЕДСТАВЛЕНИЙ О МЕХАНИЗМАХ ДЕЙСТВИЯ СУКЦИНАТСОДЕРЖАЩИХ ДИАЛИЗИРУЮЩИХ РАСТВОРОВEXPANDING THE FRONTIERS OF SUCCINATE-CONTAINING DIALYSATE’S EFFECTSГолубевР. В.GolubevR. V.

Голубев Роман Владимирович, кандидат медицинских наук, Научно-исследовательский институт нефрологии, лаборатория почечной недостаточности, зав. лабораторией. 

197022, Россия, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54.

Roman V. Golubev, PhD.

Research Institute of Nephrology, Laboratory of Renal Insufficiency, head. 

197022, Russia, St-Petersburg, L. Tolstoy st., 17, build. 54

romvladgol@gmail.comСмирновА. В.SmirnovA. V.

Профессор Смирнов Алексей Владимирович, Научноисследовательский институт нефрологии, директор. П. Павлова.  

197022, Россия, Санкт-Петербург, ул. Л. Толстого, д. 17, корп. 54.

Prof. Alexey V. Smirnov MD, PhD, DMedSci. 

Research Institute of Nephrology, director

197022, Russia, St-Petersburg, L. Tolstoy st., 17, build. 54

smirnov@nephrolog.ruПервый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияPavlov First Saint-Petersburg State Medical UniversityRussian Federation2017030320172111924Copyright © Голубев Р.В., Смирнов А.В., 20172017Голубев Р.В., Смирнов А.В.Golubev R.V., Smirnov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/217

Сукцинат является метаболитом гипоксического стресс-сигнала. Попадая в организм больного из диализирующего раствора во время сеанса гемодиализа, сукцинат ингибирует пролилгидроксилазы, что приводит к стабилизации фактора, индуцируемого гипоксией (HIF), и к развертыванию многочисленных HIF-опосредованных эффектов. Применение сукцинатсодержащих диализирующих растворов можно рассматривать как псевдогипоксическое прекондиционирование, оказывающее благоприятное действие на ряд клинико-биохимических показателей пациентов. 

Succinate is hypoxic stress signal metabolite. Entering the patient’s body from the dialysate during hemodialysis, succinate inhibits prolylhydroxylases, leading to stabilization of hypoxia-inducible factor (HIF) and to the deployment of many HIF-mediated effects. Application of succinate-containing dialysis solutions can be considered as pseudohypoxic preconditioning, which provides the beneficial effect on several clinical and biochemical parameters of patients. 

сукцинатгемодиализсукцинатсодержащий диализирующий растворфакториндуцируемый гипоксией (HIF).succinatehemodialysissuccinate-containing dialysatehypoxia-inducible factor (HIF).ReferencesCмирнов АВ, Нестерова ОБ, Голубев РВ и др. Кардиопротективные эффекты сукцинатсодержащего диализирующего раствора. Нефрология 2012; 16(2): 69-78 [Smirnov AV, Nesterova OB, Golubev RV i dr. Kardioprotektivnye e’ffekty sukcinatsoderzhashhego dializiruyushhego rastvora. Nefrologiya 2012; 16(2): 69-78]Cмирнов АВ, Нестерова ОБ, Голубев РВ и др. Кардиопротективные эффекты сукцинатсодержащего диализирующего раствора. Нефрология 2012; 16(2): 69-78 [Smirnov AV, Nesterova OB, Golubev RV i dr. Kardioprotektivnye e’ffekty sukcinatsoderzhashhego dializiruyushhego rastvora. Nefrologiya 2012; 16(2): 69-78]Смирнов АВ, Нестерова ОБ, Суглобова ЕД и др. Клинико-лабораторная оценка эффективности лечения больных с терминальной стадией почечной недостаточности с использованием хронического гемодиализа и ацидосукцината. Тер Арх 2013; 85(1): 69-75 [Smirnov AV, Nesterova OB, Suglobova ED i dr. Kliniko-laboratornaya ocenka e’ffektivnosti lecheniya bol’nyh s terminal’noj stadiej pochechnoj nedostatochnosti s ispol’zovaniem hronicheskogo gemodializa i acidosukcinata. Ter Arh 2013; 85(1): 69-75]Смирнов АВ, Нестерова ОБ, Суглобова ЕД и др. Клинико-лабораторная оценка эффективности лечения больных с терминальной стадией почечной недостаточности с использованием хронического гемодиализа и ацидосукцината. Тер Арх 2013; 85(1): 69-75 [Smirnov AV, Nesterova OB, Suglobova ED i dr. Kliniko-laboratornaya ocenka e’ffektivnosti lecheniya bol’nyh s terminal’noj stadiej pochechnoj nedostatochnosti s ispol’zovaniem hronicheskogo gemodializa i acidosukcinata. Ter Arh 2013; 85(1): 69-75]Смирнов АВ, Нестерова ОБ, Голубев РВ. Янтарная кислота и её применение в медицине. Часть II. Применение янтарной кислоты в медицине. Нефрология 2014; 18(4): 12-24 [Smirnov AV, Nesterova OB, Golubev RV. Yantarnaya kislota i eyo primenenie v medicine. Chast’ II. Primenenie yantarnoj kisloty v medicine. Nefrologiya 2014; 18(4): 12-24]Смирнов АВ, Нестерова ОБ, Голубев РВ. Янтарная кислота и её применение в медицине. Часть II. Применение янтарной кислоты в медицине. Нефрология 2014; 18(4): 12-24 [Smirnov AV, Nesterova OB, Golubev RV. Yantarnaya kislota i eyo primenenie v medicine. Chast’ II. Primenenie yantarnoj kisloty v medicine. Nefrologiya 2014; 18(4): 12-24]Смирнов АВ, Голубев РВ, Васильев АН и др. Гемодинамические эффекты содержащего сукцинат диализирующего раствора. Тер Арх 2015; 87(6): 56-61. doi: 10.17116/ terarkh201587656-61 [Smirnov AV, Golubev RV, Vasil’ev AN i dr. Gemodinamicheskie e’ffekty soderzhashhego sukcinat dializiruyushhego rastvora. Ter Arh 2015; 87(6): 56-61. doi: 10.17116/terarkh201587656-61]Смирнов АВ, Голубев РВ, Васильев АН и др. Гемодинамические эффекты содержащего сукцинат диализирующего раствора. Тер Арх 2015; 87(6): 56-61. doi: 10.17116/ terarkh201587656-61 [Smirnov AV, Golubev RV, Vasil’ev AN i dr. Gemodinamicheskie e’ffekty soderzhashhego sukcinat dializiruyushhego rastvora. Ter Arh 2015; 87(6): 56-61. doi: 10.17116/terarkh201587656-61]Смирнов АВ, Нестерова ОБ, Голубев РВ, Лазеба ВА. Сукцинатсодержащие диализирующие растворы в практике гемодиализа. Левша, СПб., 2014; 73-82 [Smirnov AV, Nesterova OB, Golubev RV, Lazeba VA. Sukcinatsoderzhashhie dializiruyushhie rastvory v praktike gemodializa. Levsha, SPb, 2014; 73-82]Смирнов АВ, Нестерова ОБ, Голубев РВ, Лазеба ВА. Сукцинатсодержащие диализирующие растворы в практике гемодиализа. Левша, СПб., 2014; 73-82 [Smirnov AV, Nesterova OB, Golubev RV, Lazeba VA. Sukcinatsoderzhashhie dializiruyushhie rastvory v praktike gemodializa. Levsha, SPb, 2014; 73-82]Benit P, Letouze E, Rak M et al. Unsuspected task for an old team: succinate, fumarate and other Krebs cycle acids in metabolic remodeling. Biochim Biophys Acta 2014; 1837(8): 1330-1337. doi: 10.1016/j.bbabio.2014.03.013Benit P, Letouze E, Rak M et al. Unsuspected task for an old team: succinate, fumarate and other Krebs cycle acids in metabolic remodeling. Biochim Biophys Acta 2014; 1837(8): 1330-1337. doi: 10.1016/j.bbabio.2014.03.013Glissen J, Jouret F, Pirotte B, Hanson J. Insight into SUCNR1 (GPR91) structure and function. Pharmacol Ther 2016; doi: 10.1016/j.pharmthera.2016.01.008 [Epub ahead of print]Glissen J, Jouret F, Pirotte B, Hanson J. Insight into SUCNR1 (GPR91) structure and function. Pharmacol Ther 2016; doi: 10.1016/j.pharmthera.2016.01.008 [Epub ahead of print]Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. BBA – Bioenergetics 2016; doi: 10.1016/j.bbabio.2016.03.012 [Epub ahead of print]Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. BBA – Bioenergetics 2016; doi: 10.1016/j.bbabio.2016.03.012 [Epub ahead of print]Antonio C, Papke C, Rocha M et al. Regulation of primary metabolism in response to low oxygen availability as revealed by carbon and nitrogen isotope redistribution. Plant Physiol 2016; 170(1): 43-56. doi: 10.1104/pp.15.00266 10. Titov D, Cracan V, Goodman R et al. Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio. Science 2016; 352(6282): 231-235. doi: 10.1126/science.aad4017Antonio C, Papke C, Rocha M et al. Regulation of primary metabolism in response to low oxygen availability as revealed by carbon and nitrogen isotope redistribution. Plant Physiol 2016; 170(1): 43-56. doi: 10.1104/pp.15.00266 10. Titov D, Cracan V, Goodman R et al. Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio. Science 2016; 352(6282): 231-235. doi: 10.1126/science.aad4017Kiss G, Konrad C, Pour-Ghaz I et al. Mitochondrial diaphorases as NAD+ donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition. FASEB J 2014; 28(4): 1682-1697. doi: 10.1096/fj.13-243030Kiss G, Konrad C, Pour-Ghaz I et al. Mitochondrial diaphorases as NAD+ donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition. FASEB J 2014; 28(4): 1682-1697. doi: 10.1096/fj.13-243030Qutub A, Popel A. Three autocrine feedback loops determine HIF1α expression in chronic hypoxia. Biochim Biophys Acta 2007; 1773(10): 1511-1525. doi: 10.1016/j.bbamcr.2007.07.004Qutub A, Popel A. Three autocrine feedback loops determine HIF1α expression in chronic hypoxia. Biochim Biophys Acta 2007; 1773(10): 1511-1525. doi: 10.1016/j.bbamcr.2007.07.004Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs 2016; doi: 10.1080/13543784.2016.1182981 [Epub ahead of print]Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs 2016; doi: 10.1080/13543784.2016.1182981 [Epub ahead of print]Schonenberger M, Kovacs W. Hypoxia signaling pathways: modulators of oxygen-related organelles. Front Cell Dev Biol 2015; 3: 42. doi: 10.3389/fcell.2015.00042Schonenberger M, Kovacs W. Hypoxia signaling pathways: modulators of oxygen-related organelles. Front Cell Dev Biol 2015; 3: 42. doi: 10.3389/fcell.2015.00042Semenza G. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148(3): 399-408. doi: 10.1016/j.cell.2012.01.021Semenza G. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148(3): 399-408. doi: 10.1016/j.cell.2012.01.021Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85(3): 1093–1129. doi: 10.1152/physrev.00006.2004Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85(3): 1093–1129. doi: 10.1152/physrev.00006.2004Ingwall JS. Energy metabolism in heart failure and remodeling. Cardiovasc Res 2009; 81(3): 412-419. doi: 10.1093/cvr/cvn301Ingwall JS. Energy metabolism in heart failure and remodeling. Cardiovasc Res 2009; 81(3): 412-419. doi: 10.1093/cvr/cvn301Тугушева ФА, Куликова АИ, Коношкова РЛ. О влиянии предуктала-20 на ишемию миокарда и показатели липопероксидации в крови больных с хронической почечной недостаточностью, получающих регулярный гемодиализ. Нефрология 1997; 1(2): 73-78 [Tugusheva FA, Kulikova AI, Konoshkova RL. O vliyanii preduktala-20 na ishemiyu miokarda i pokazateli lipoperoksidacii v krovi bol'nyh s hronicheskoj pochechnoj nedostatochnost’yu, poluchayushhih regulyarnyj gemodializ. Nefrologiya 1997; 1(2): 73-78]Тугушева ФА, Куликова АИ, Коношкова РЛ. О влиянии предуктала-20 на ишемию миокарда и показатели липопероксидации в крови больных с хронической почечной недостаточностью, получающих регулярный гемодиализ. Нефрология 1997; 1(2): 73-78 [Tugusheva FA, Kulikova AI, Konoshkova RL. O vliyanii preduktala-20 na ishemiyu miokarda i pokazateli lipoperoksidacii v krovi bol'nyh s hronicheskoj pochechnoj nedostatochnost’yu, poluchayushhih regulyarnyj gemodializ. Nefrologiya 1997; 1(2): 73-78]Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLOS One 2014, 9(5), e94660. doi: 10.1371/journal.pone.0094660Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLOS One 2014, 9(5), e94660. doi: 10.1371/journal.pone.0094660Anderson E, Xue X, Shah Y. Intestinal hypoxia-inducible factor-2α (HIF-2 α) is critical for efficient erythropoiesis. J Biol Chem 2011; 286(22): 19533-19540. doi: 10.1074/jbc.M111.238667Anderson E, Xue X, Shah Y. Intestinal hypoxia-inducible factor-2α (HIF-2 α) is critical for efficient erythropoiesis. J Biol Chem 2011; 286(22): 19533-19540. doi: 10.1074/jbc.M111.238667Barrett TD, Palomino HL, Brondstetter TI et al. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol 2015; 172(16): 4078-4088. doi: 10.1111/bph.13188Barrett TD, Palomino HL, Brondstetter TI et al. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol 2015; 172(16): 4078-4088. doi: 10.1111/bph.13188Titze J, Machnic A. Sodium sensing in the interstitium and relationship to hypertension. Curr Opin Nephrol Hypertens 2010; 19(4): 385-392. doi: 10.1097/MNH.0b013e32833aeb3bTitze J, Machnic A. Sodium sensing in the interstitium and relationship to hypertension. Curr Opin Nephrol Hypertens 2010; 19(4): 385-392. doi: 10.1097/MNH.0b013e32833aeb3bTitze J, Dahlmann A, Lerchl K et al. Spooky sodium balance. Kidney Int 2013; 85(4): 759-767. doi: 10.1038/ki.2013.367Titze J, Dahlmann A, Lerchl K et al. Spooky sodium balance. Kidney Int 2013; 85(4): 759-767. doi: 10.1038/ki.2013.367Titze J, Muller DN, Luft FC. Taking another “look” at sodium. Can J Cardiol 2014; 30(5): 473-475. doi: 10.1016/j.cjca.2014.02.006Titze J, Muller DN, Luft FC. Taking another “look” at sodium. Can J Cardiol 2014; 30(5): 473-475. doi: 10.1016/j.cjca.2014.02.006Murry C, Jennings R, Reimer K. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74(5): 1124–1136. doi: 10.1161/01.CIR.74.5.1124Murry C, Jennings R, Reimer K. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74(5): 1124–1136. doi: 10.1161/01.CIR.74.5.1124Kitagawa K, Matsumoto M, Tagaya M. et al. «Ischemic tolerance» phenomenon found in the brain. Brain Res 1990; 528(1): 21–24. doi: 10.1016/0006-8993(90)90189-IKitagawa K, Matsumoto M, Tagaya M. et al. «Ischemic tolerance» phenomenon found in the brain. Brain Res 1990; 528(1): 21–24. doi: 10.1016/0006-8993(90)90189-IRybnikova E, Samoilov M. Cuttent insights into the molecular mechanisms of hypoxic preand postconditioning using hypobaric hypoxia. Front Neurosci 2015; 9: 388. doi: 10.3389/fnins.2015.00388Rybnikova E, Samoilov M. Cuttent insights into the molecular mechanisms of hypoxic preand postconditioning using hypobaric hypoxia. Front Neurosci 2015; 9: 388. doi: 10.3389/fnins.2015.00388Calabrese V, Cornelius C, Dinkova-Kostova A et al. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 2010; 13(11): 1763-1811. doi: 10.1089/ars.2009.3074Calabrese V, Cornelius C, Dinkova-Kostova A et al. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 2010; 13(11): 1763-1811. doi: 10.1089/ars.2009.3074Samaja M, Milano G. Editorial – Hypoxia and reoxygenation: from basic science to bedside. Front Pediatr 2015; 3: 86. doi:10.3389/fped.2015.00086Samaja M, Milano G. Editorial – Hypoxia and reoxygenation: from basic science to bedside. Front Pediatr 2015; 3: 86. doi:10.3389/fped.2015.00086Besarab A, Provenzano R, Hertel J et al. Randomised placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Neprol Dial Transplant 2015; 30(10): 1665-1673. doi: 10.1093/ndt/gfv302Besarab A, Provenzano R, Hertel J et al. Randomised placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Neprol Dial Transplant 2015; 30(10): 1665-1673. doi: 10.1093/ndt/gfv302Provenzano R, Besarab A, Wright S et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. AJKD 2016; doi: 10.1053/j.ajkd.2015.12.020 [Epub ahead of print]Provenzano R, Besarab A, Wright S et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. AJKD 2016; doi: 10.1053/j.ajkd.2015.12.020 [Epub ahead of print]Lee K, Kim HM. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Arch Pharm Res 2011; 34(10): 1583-1585. doi: 10.1007/s12272-011-1021-3Lee K, Kim HM. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Arch Pharm Res 2011; 34(10): 1583-1585. doi: 10.1007/s12272-011-1021-3Hu Y, Liu J, Huang H. Recent agents targeting HIF-1α for cancer therapy. J Cell Biochem 2013; 114(3): 498-509. doi: 10.1002/jcb.24390Hu Y, Liu J, Huang H. Recent agents targeting HIF-1α for cancer therapy. J Cell Biochem 2013; 114(3): 498-509. doi: 10.1002/jcb.24390Ali S, Oni E, Waraich H et al. Systematic review on noninvasive assessment of subclinical cardiovascular disease in obstructive sleep apnea: new kid on the block! Sleep Med Rev 2014; 18(5): 379-381. doi: 10.1016/j.smrv.2014.01.004Ali S, Oni E, Waraich H et al. Systematic review on noninvasive assessment of subclinical cardiovascular disease in obstructive sleep apnea: new kid on the block! Sleep Med Rev 2014; 18(5): 379-381. doi: 10.1016/j.smrv.2014.01.004Chouchani E, Pell V, Gaude E et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014; 515(7527): 431-435. doi:10.1038/nature13909Chouchani E, Pell V, Gaude E et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014; 515(7527): 431-435. doi:10.1038/nature13909Schmidt H, Stocker R, Vollbracht C et al. Antioxidants in translational medicine. Antioxid Redox Signal 2015; 23(14): 11301143. doi: 10.1089/ars.2015.6393Schmidt H, Stocker R, Vollbracht C et al. Antioxidants in translational medicine. Antioxid Redox Signal 2015; 23(14): 11301143. doi: 10.1089/ars.2015.6393Zhang H, Limphong P, Pieper J et al. Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J 2012; 26(4): 1442-1451. doi: 10.1096/fj.11-199869Zhang H, Limphong P, Pieper J et al. Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J 2012; 26(4): 1442-1451. doi: 10.1096/fj.11-199869Veal E, Day A, Morgan B. Hydrogen peroxide sensing and signaling. Mol Cell Rev 2007; 26(1): 1-14. doi: 10.1016/j.molcel.2007.03.016Veal E, Day A, Morgan B. Hydrogen peroxide sensing and signaling. Mol Cell Rev 2007; 26(1): 1-14. doi: 10.1016/j.molcel.2007.03.016Al-Mehdi A-B, Pastukh V, Swiger B et al. Perinuclear mitochondrial clustering creates an oxidant-reach nuclear domain required for hypoxia-induced transcription. Sci Signal 2012; 5(231): ra47. doi: 10.1126/scisignal.2002712Al-Mehdi A-B, Pastukh V, Swiger B et al. Perinuclear mitochondrial clustering creates an oxidant-reach nuclear domain required for hypoxia-induced transcription. Sci Signal 2012; 5(231): ra47. doi: 10.1126/scisignal.2002712Powers S, Smuder A, Kavazis A, Quindry J. Mechanisms of exercise-induced cardioprotection. Physiology(Bethesda) 2014; 29(1):27-38. doi: 10.1152/physiol.00030.2013Powers S, Smuder A, Kavazis A, Quindry J. Mechanisms of exercise-induced cardioprotection. Physiology(Bethesda) 2014; 29(1):27-38. doi: 10.1152/physiol.00030.2013Ristow M, Zarse K, Oberbach A et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009; 106(21): 8665–8670. doi: 10.1073/pnas.0903485106Ristow M, Zarse K, Oberbach A et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009; 106(21): 8665–8670. doi: 10.1073/pnas.0903485106Merkley E, Metz T, Smith R. The succinated proteome. Mass Spectrom Rev 2014; 33(2): 98-109. doi: 10.1002/mas.21382Merkley E, Metz T, Smith R. The succinated proteome. Mass Spectrom Rev 2014; 33(2): 98-109. doi: 10.1002/mas.21382Kuo C-Y, Cheng C-T, Hou P et al. HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breаst cancer tumorigenicity. Oncotarget 2016; doi: 10.18632/oncotarget.8570 [Epub ahead of print]Kuo C-Y, Cheng C-T, Hou P et al. HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breаst cancer tumorigenicity. Oncotarget 2016; doi: 10.18632/oncotarget.8570 [Epub ahead of print]Gibson G, Xu H, Chen H-L et al. Alpha-ketoglutarate dehydrogenase complex-dependent succinilation of proteins in neurons and neuronal cell lines. J Neurochem 2015; 134(1): 8696. doi: 10.1111/jnc.13096Gibson G, Xu H, Chen H-L et al. Alpha-ketoglutarate dehydrogenase complex-dependent succinilation of proteins in neurons and neuronal cell lines. J Neurochem 2015; 134(1): 8696. doi: 10.1111/jnc.13096McKenna M, Rae C. A new role for α-ketoglutarate dehydrogenase complex: regulating metabolism through posttranslational modification of other enzymes. J Neurochem 2015; 134(1): 3-6. doi: 10.1111/jnc.13150McKenna M, Rae C. A new role for α-ketoglutarate dehydrogenase complex: regulating metabolism through posttranslational modification of other enzymes. J Neurochem 2015; 134(1): 3-6. doi: 10.1111/jnc.13150

The authors declare that there are no conflicts of interest present.